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The present paper describes possible connections between antiretroviral therapies (ARTs) used to treat human immunodeﬁciency
virus (HIV) infection and adverse drug reactions (ADRs) encountered predominantly in the liver, including hypersensitivity
syndrome reactions, as well as throughout the gastrointestinal system, including the pancreas. Highly active antiretroviral therapy
(HAART) has a positive inﬂuence on the quality of life and longevity in HIV patients, substantially reducing morbidity and
mortality in this population. However, HAART produces a spectrum of ADRs. Alcohol consumption can interact with HAART
as well as other pharmaceutical agents used for the prevention of opportunistic infections such as pneumonia and tuberculosis.
OthercoinfectionsthatoccurinHIV,suchashepatitisvirusesBorC,cytomegalovirus,orherpessimplexvirus,furthercomplicate
the etiology of HAART-induced ADRs. The aspect of liver pathology including liver structure and function has received little
attention and deserves further evaluation. The materials used provide a data-supported approach. They are based on systematic
review and analysis of recently published world literature (MedLine search) and the experience of the authors in the speciﬁed
topic. We conclude that therapeutic and drug monitoring of ART, using laboratory identiﬁcation of phenotypic susceptibilities,
drug interactions with other medications, drug interactions with herbal medicines, and alcohol intake might enable a safer use of
this medication.
1.Introduction
Knowledge about indications for antiretroviral therapy
(ART) use in chronically human immunodeﬁciency virus
(HIV-) infected patients, relative eﬃcacy of diﬀerent reg-
imens, patient evaluation, and laboratory monitoring are
essential in the success of viral eradication. There are
diﬀerent combination therapies presenting activity against
both wild-type and multidrug resistant HIV.
Side eﬀects of these therapeutic interventions include
adverse drug reactions (ADRs) such as direct hepato-
cytotoxicity, hypersensitivity syndrome reactions (HSRs),
nausea, headache, diarrhea, and pancreatic toxicity. An ADR
representsanynoxious,unintended,andundesiredeﬀectofa
drug, which occurs at doses used in humans for prophylaxis,
diagnosis, or therapy [1].
Pharmaceutical agents that can be combined to make up
highly active antiretroviral therapy (HAART) can be divided
into three categories, namely, nucleoside reverse transcrip-
tase inhibitors (NRTIs), nonnucleoside reverse transcriptase
inhibitors (NNRTIs), and protease inhibitors (PIs), based
on their mechanism of action. Substrates of P-glycoprotein,
an ATP-dependent eﬄux membrane multidrug resistance
transporter, comprise one class of molecules that can limit
the absorption of most PIs. For example, oral administration
of saquinavir, indinavir, or nelﬁnavir in knockout mice
lacking this transporter resulted in two- to ﬁvefold increases
in plasma drug concentrations [2]. Higher plasma drug2 International Journal of Hepatology
concentrations can therefore produce toxicities in human
patients that might lack P-glycoprotein.
While drug interactions should be examined closely
whenever prescribing medication in combination with PIs,
this is a particularly important consideration with ritonavir,
given its powerful inhibition of cytochrome p450 (CYP)
3A4 and its eﬀects on several other mechanisms of drug
interactions [3]. These can lead to increased levels of
many coadministered medications, and consequently ADRs.
Moreover, there is a potential for interaction with nutritional
supplements [4].
Physicians should also be aware that patients with
chronic viral hepatitis coinfection have additional impair-
ment of CYP3A activity in the presence of ritonavir, com-
pared to HIV patients without viral hepatitis, even at the
low doses of 100mg/day typically used for pharmacokinetic
boosting [61].
The various ADRs associated with ART use encountered
predominantly in the liver, including HSRs, as well as
throughout the gastrointestinal (GI) system, including the
pancreas, are presented hereinafter and summarized in
Table 1.
2. Hepatotoxicity
Mendes-Corrˆ ea et al. argue that liver damage exists in HIV
patients independent of ART exposure [62].
In general, severe hepatic injury occurs in HAART
patients, regardless of their treatment [63]. In his last
published work, Zimmerman stated unequivocally that the
necroinﬂammatory changes that can be seen in drug-
related hepatotoxicity can overlap with those of chronic viral
hepatitis [64].
The importance of histological changes in the diagnosis
of drug-induced toxicity, its disease spectrum, and the
ﬁne structures of hepatocytotoxicity are considered in the
discussionsection.Inthepresentsection,webringforthonly
evidence shown by investigators in their work, which is also
summarized in Table 1.
Careful review of medication, both prescription and
nonprescription, should be compiled in patients with new
symptoms or signs of hepatitis, in order to address the
possibility of drug toxicity.
Hepatic mitochondrial damage was found in ART-naive
patients as well as patients exposed to the NRTIs zidovudine
or didanosine [62]. The intensity of dense granules was
higher in mitochondria from previously untreated patients,
compared to current ART patients (P<0.05). Qualitative
analyses showed areas of mitochondrial hyperplasia, with
changes in shape (elongation, baloonization, bizarre shapes)
and size (megamitochondria) in both groups. There were
also increases in the numbers of dense granules, matrix
condensation, crista loss, lamellar distributed ﬁlamentous
material, and crystalloid material [62].
T h el e v e l so f13C-methionine exhaled, a measure of
hepatic mitochondrial function, increased signiﬁcantly in
ART-naivepatientsaftertreatmentinitiation(P<0.001)[5].
13C exhalation continued to decrease in ART-naive patients
whocontinuedtoremainnaive(P = 0.04),aswellaspatients
who stopped treatment (P = 0.043). No changes in the 13C-
methionine breath test results were observed among ART-
experienced patients who did not change their treatment
(P = 0.31) or changed only the PI and NNRTI components
of their treatments (P = 0.34), or among patients who
remained on structured treatment interruption (P = 0.068).
Reinitiation of ART led to signiﬁcant improvements (P =
0.008) [5]. A switch from didanosine or stavudine to
tenofovir or abacavir also led to a signiﬁcant improvement
in 13C-methionine breath test performance (P<0.001) [5].
Hepatotoxicity is a relatively common ADR leading to
treatment interruptions in HIV patients, observed with
diﬀerent drug combinations (Table 1)[ 6–27]. Among these,
nevirapine was often associated with the development of
hepatotoxicity [8, 9, 12, 13, 15, 16, 18, 20, 22, 23, 25].
Nevirapine use was associated with a higher incidence
of liver toxicity than efavirenz use [14]. The use of PIs
in combination with either efavirenz or nevirapine was
associated with an increased risk of hepatotoxicity compared
to efavirenz or nevirapine alone (odds ratio (OR) 3.07, 95%
conﬁdence interval (CI) 1.01–9.32, P = 0.04) [65].
Increases in liver enzymes are also common ADRs
characteristic of diﬀerent ART regimens (Table 1)[ 20, 28–
35, 66]. Increases in alanine aminotransferase (ALT) or/and
aspartate aminotransferase (AST) are common symptoms of
hepatotoxicity,whileincreasesinalkalinephosphataseandγ-
glutamyl transpeptidase were indicative of cholestasis in one
study [66].
The median delay between HAART initiation and occur-
rence of hepatotoxicity was 2.5 months (interquartile range
(IQR) 1 to 11 months) in one study [17] and 5 weeks (IQR 3
to 29 weeks) in another study [18]. While a similar number
of patients discontinued nevirapine due to hepatotoxicity
before month 3 and after a mean number of 9 months in
another study [13], van Griensven et al. observed that only
27.6% of 29 cases of nevirapine hepatotoxicity occurred after
6 months of treatment [18].
One study found hepatitis to occur with a similar fre-
quency among zidovudine/lamivudine, zidovudine/didano-
sine, or stavudine/lamivudine patients [27], whereas a sepa-
rate study found a higher incidence of hepatotoxicity among
stavudine/lamivudine patients [19].
Hepatic events were the most common drug ADRs
associated with atazanavir/ritonavir [24]. Jaundice was also
observed among atazanavir/ritonavir patients [24, 33, 36],
but not among lopinavir/ritonavir patients [33]. Similarly,
grade ≥3 increases in total bilirubin levels occurred more
frequently in the atazanavir/ritonavir group than in the
lopinavir/ritonavir group [33]. Acute liver failure, accom-
panied by jaundice, fever, vomiting, and hepatomegaly,
was observed in a 10-year-old male [67]. The patient’s
condition started improving following liver transplantation
and replacement of efavirenz with raltegravir [67]. Bilirubin
levels did not aﬀect the rate of hepatotoxicity in another
study [35]. Grade 3 hyperbilirubinemia/liver toxicity was
also observed with nevirapine [21].
Unconjugated bilirubin levels should be monitored in


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































]International Journal of Hepatology 15
glucuronosyltransferase (UGT) mediates conjugation of
bilirubin.
Hyperbilirubinemia is an adverse eﬀect that occurs in
approximately 25% of indinavir patients, with total bilirubin
rises to the 2.5 to 5mg/dL range [68]. This represents largely
indirect bilirubin and is insigniﬁcant except as a possible
complication of pregnancy [68, 69]. Atazanavir also appears
to impair UGT activity [70], such that the PIs atazanavir
and indinavir are associated with hyperbilirubinemia. The
relationship between underlying genetic risk factors and
the risk of developing hyperbilirubinemia remains unclear.
UGT1A1∗28 allele was associated with jaundice in a study
in which bilirubin levels were not measured [24]. In a
study of patients who underwent genotypic analysis for
polymorphisms associated with increased unconjugated
bilirubin, 64 (66.7%) of 96 patients were positive for
the UGT1A1∗28 allele. [70]. Ocama et al. found that 23
(29.9%) of 77 consecutive HIV-infected patients presenting
with hepatotoxicity (jaundice, right upper quadrant pain
with fever or malaise, ascites, and/or tender hepatomegaly)
had increased transaminase levels as a result of nevirapine
and/or isoniazid hepatotoxicity [71]. Of these 23 patients
with drug-induced liver disease, 14 (60.9%) presented with
jaundice and recovered after drug discontinuation. Hepatitis
B surface antigen was positive in 11 (14.3%) patients while
antihepatitis C antibody was reactive in only 2 (2.6%).
Granulomatous hepatitis due to tuberculosis was diagnosed
in7(9.1%)patients.Otherdiagnosesincludedalcoholicliver
disease, AIDS cholangiopathy, hepatocellular carcinoma,
schistosomiasis, hemangioma, and hepatic adenoma. Twelve
(15.6%) patients died during follow-up, of which 7 (9.1%)
died because of liver disease [71].
The overall incidence of severe hepatic injury was not
signiﬁcantly diﬀerent between NRTIs, NNRTIs, and PIs in a
sample of 222 patients, of which 84 (37.8%) were coinfected
withhepatitisCvirus(HCV)[63].Coinfectionwithhepatitis
virusesisoftenassociatedwithahigherriskofhepatotoxicity
[63, 65]; however this is not always the case [24]. Elevated
baseline liver function tests and older age are additional risk
factors for hepatotoxicity [18].
3.HypersensitivitySyndromeReaction
HSRs have been associated with the NRTI abacavir, the
NNRTIs nevirapine and efavirenz, and the PI amprenavir
[72–74]. The potential for HSR development symbolizes a
treatment-limiting and potentially life-threatening ADR.
Abacavir HSR is the major treatment-limiting toxicity of
HAART regimens containing this drug. This ADR usually
occurs in the ﬁrst 6 weeks of treatment [75]. An HSR
characterized by some combination of ﬂu-like symptoms,
fever, rash, as well as GI symptoms, including hepatotoxicity,
generally occurs in 3–5% of patients starting abacavir
[76]. Other symptoms of HSR include malaise, lethargy,
myalgia, myolysis, arthralgia, edema, pharyngitis, cough,
dyspnea, headache, and paresthesia. Physical ﬁndings may
include lymphadenopathy, mucous membrane lesions (i.e.,
conjunctivitis, mouth ulcerations), and rash, which usually
appears as maculopapular or urticarial, but can also lead to
Stevens-Johnson syndrome (SJS).
Diﬀerentiation between abacavir HSR and viral respira-
toryinfectionscanbeproblematic.Rash(OR13.1,P = 0.02),
nausea (OR 30, P<0.001), vomiting (OR 17.1, P = 0.001),
and diarrhea (OR 22, P<0.001) were associated with
HSR in 15 cases of abacavir HSR matched with 30 controls
with culture-proven inﬂuenza A with no abacavir exposure
[77] .T h en u m b e ro fG Is y m p t o m sw a sa l s op r e d i c t i v eo f
HSR (P<0.001). Multivariate analysis conﬁrmed that the
number of GI symptoms (OR 8.6, P = 0.0032) and rash
(OR 16.9, P = 0.07) was associated with abacavir HSR.
AbacavirHSR-associatedrashwastypicallymildtomoderate
in this study, occurring after an average of 9–11 days since
treatment initiation [77]. Abacavir HSR was found to resolve
itself rapidly following treatment modiﬁcations [37]. This
r e a c t i o nw a so b s e r v e di no t h e rs t u d i e sa sw e l l[ 36–41].
Abacavir HSR is strongly associated with GI symptoms
[77]. Laboratory abnormalities include elevated liver func-
tion tests, increased creatine phosphokinase or creatinine,
and lymphopenia. Liver failure and death have occurred
in association with HSR. Symptoms associated with HSR
worsen with continued therapy but often resolve upon
discontinuation of the drug [78, 79].
ItishighlyrecommendedthatHSRpatientsavoidrechal-
l e n g ew i t hf u l l - d o s ea b a c a v i r ,a se x t r e m e l ys e v e r es y m p t o m s
and even death may result [80]. Reports describe the
mechanisms of action, eﬃcacy, and ADRs of abacavir in
HIV-1-infected patients and illustrate the danger of serially
rechallenging patients with this agent even if the patient was
previously desensitized [78, 81–83].
A strong statistical association was identiﬁed between
the human leukocyte antigen (HLA)-B∗5701 allele, part
of the major histocompatibility complex, and clinically
diagnosed abacavir HSR [84]. While abacavir HSR occurs in
approximately 5% of HIV patients treated with this drug,
the HLA-B∗5701 allele was discovered in 6.3% of 11000
genetic screens performed in a Canadian population [75].
As a consequence, prospective HLA-B∗5701 screening is
performed to identify patients at high risk for abacavir HSR
before they are treated [85]. Genetic screening of potential
abacavir patients can greatly help prevent HSRs and it
can lead to individualizing of HAART in order to prevent
toxicity and to improve adherence [75]. Carriers of HLA-
B∗5701 should avoid abacavir-based HAART [84, 86–91].
Despite prior HLA genotyping, the incidence of abacavir
HSR was higher in an abacavir/lamivudine-based regimen
compared to a tenofovir/emtricitabine-based regimen [40,
41].Thisphenomenonindicatesthatanadditionalmetabolic
or immune mechanism might contribute to the ADR.
Approximately 17% of patients starting nevirapine and
10% of patients starting efavirenz will develop rash of
varying severity with or without systemic features, typically
between 1 and 3 weeks after starting the drug [92]. As
HLA genotyping has the potential to reduce the incidence
of abacavir HSR, nevirapine is the pharmaceutical agent
most often associated with cutaneous HSRs (Table 1)[ 9–
14, 16–18, 20–25, 31, 39, 42–48]. Moreover, Warren et al.
[93] report that nevirapine can be associated with SJS. Albeit16 International Journal of Hepatology
infrequent, SJS and toxic epidermal necrolysis (TEN) are
sometimes observed in conjunction with nevirapine and can
be fatal [9, 13, 31, 45, 48, 49]. The median time for skin
rash occurrence was 1.0 month (IQR 3 weeks to 3 months)
[17, 18, 45]. The majority of patients who discontinued
nevirapine due to HSR did so within 18 weeks (for both skin
rashandhepatotoxicitywithoutconcomitantskinrash)[47].
Hepatitis is observed with relative frequency in HSR
patients [15, 45, 48]. No patient suﬀered from both skin
rash and liver abnormality in other studies [8, 11, 44, 47].
Hepatic involvement in HSR can also be observed without
concomitant cutaneous reactions [44, 47].
Nevirapine-associated HSRs are usually moderate to
severeandoftenrequiretreatmentchangefortheelimination
of the agent that caused the reaction [8, 9, 13, 15, 16, 18,
20, 23, 31, 42, 44–46]. Nevirapine is usually substituted
with efavirenz in HSR cases [42]. Dermal lesions were
observed only in combinations that contained nevirapine
and lamivudine in one study [66]. There was a higher
incidence of severe rashes (grade ≥3) among nevirapine
patients, compared to nonnevirapine patients (P = 0.002)
in another study. While the same trend was observed overall
for grade ≥2 rash, this association was no longer signiﬁcant
(P = 0.099) [31]. Efavirenz itself has been associated with
skin symptoms [20, 50]. In such cases, a switch to nevirapine
often results in the development of similar reactions on
nevirapine as well, showing cross-reactivity between the
two NNRTIs [20]. Efavirenz treatment did not lead to the
development of cutaneous HSRs in a separate study [25].
The HLA-DRB1∗01 allele was signiﬁcantly associated
with isolated rash alone in patients exposed to nevirapine
or efavirenz (P = 0.04), whereas immunologic and genetic
factors are associated with hepatotoxicity and systemic ADRs
[51].
Lopinavir/ritonavir [50] and atazanavir/ritonavir [24]
were also associated with HSR. Among other NRTIs, the
development of rash led to zidovudine and stavudine
substitution [30] and the development of pruritis led to
didanosine substitution [35] in other studies.
There are also studies in which the drugs responsible for
the HSR are not speciﬁed, but certain hypotheses can be
made based on the medication regimen. In such instances,
patients are often exposed to either nevirapine or efavirenz
[19, 52].
Older age (P<0.003) and a higher CD4+ cell count
(P<0.03) were predictors of rash development [42]. No
signiﬁcant diﬀerences in plasma nevirapine concentrations
were observed between patients who experienced skin rash
and patients who did not [14]; however signiﬁcantly more
cases of grade ≤2 rash were identiﬁed in a group receiving
a full dose of nevirapine, compared to a half-dose of the
drug (P = 0.003) [42]. A strong association between grade
≥2 rash and nevirapine-based treatment was observed when
only subjects with CD4+ >250cells/mm3 were considered
(P = 0.001),suggestinganinteractionbetweenthetreatment
and the CD4+ count [42].
Inaddition,atrendofincreasingriskofdevelopinggrade
≥2 rash was observed in pregnant subjects (P = 0.054).
Pregnant subjects with baseline CD4+ >250cells/mm3 were
signiﬁcantly at risk of developing grade ≥2r a s h( P =
0.042). However, pregnancy alone is not a predictor of ADR
development for women initiating nevirapine therapy. This
is an important ﬁnding, as pregnant women were both more
likely to start nevirapine-based treatment (P<0.001) and
to have higher baseline CD4+ counts (P<0.001) [31]. No
independent risk factors for skin rash were identiﬁed in a
separate study [18].
4. GastrointestinalIntolerance
GI complaints, mainly diarrhea, vomiting, and abdominal
disturbances, were the most frequently observed ADRs in
several studies [24, 53]. These types of ADRs appeared
mainly during the ﬁrst 12 weeks of therapy and were
mild (grade ≤2) and transient in most patients [53].
Gastroenterological intolerance (dyspepsia, nausea, vomit-
ing, and diarrhea) is common eﬀects of diﬀerent drug
combinations [66]. GI intolerance was the main cause
of lopinavir/ritonavir therapy modiﬁcation or interruption
(Table 1)[ 24, 32, 33, 36, 54]. GI symptoms associated with
lopinavir/ritonavir and tipranavir were the most common
type of ADRs in patients exposed to these pharmaceu-
tical agents [55]. Cases of GI toxicity associated with
lopinavir/ritonavir discontinuation occurred between day 3
a n dw e e k1 5[ 56]. While diarrhea was the most common
ADR that led to lopinavir/ritonavir treatment changes,
this ADR was less commonly associated with efavirenz
discontinuations [26]. Compared with patients assigned to
efavirenz, patients assigned to lopinavir/ritonavir had higher
rates of nausea, diarrhea, and vomiting (P<0.01) [57].
Nevirapine is another drug associated with a high rate
of treatment discontinuations as result of GI intolerance [22,
23,47].NevirapinediscontinuationscausedbyGIsymptoms
often occur within the ﬁrst 18 weeks of treatment [47].
The incidence of GI ADRs (mainly diarrhea) was higher
in patients treated with nelﬁnavir compared to patients
treated with nevirapine (P = 0.01) [22]. Vomiting and
diarrhea were observed in other samples of patients treated
with nelﬁnavir [28, 56].
GI intolerance was the main cause of saquinavir ther-
apy modiﬁcation or interruption as well [36]. A higher
saquinavir Cmin was associated with a higher incidence of
serious GI ADRs [58]. In addition, higher saquinavir Cmin
was more prevalent in individuals with grade ≥3G Is i d e
eﬀects, compared with individuals with grade ≤2G Is i d e
eﬀects (P = 0.028) [58]. Mild nausea and diarrhea were also
observed among saquinavir patients [59].
No patient on atazanavir/ritonavir discontinued treat-
ment due to GI intolerance. More patients receiving
lopinavir/ritonavir experienced grade ≥2 nausea, compared
to patients receiving atazanavir/ritonavir [33].
GI symptoms were associated with treatment modiﬁ-
cations in patients receiving treatment with dual-boosted
PIs [94]. The drugs responsible for the observed ADRs are
not speciﬁed [94]. GI toxicity was also reported in relation
to didanosine [34]. Patients assigned to zidovudine and
didanosine had higher rates of nausea, constipation, andInternational Journal of Hepatology 17
fatigue when compared to patients assigned to stavudine and
lamivudine (P<0.05) [57]. Drug-related GI toxicity leads to
poor medication adherence and ultimate virological failure
[34]. Mild GI intolerance that did not require treatment
modiﬁcations was observed in a couple of other studies
[46, 95].
5.PancreaticToxicity
Acute pancreatitis is an inﬂammatory condition of the pan-
creas characterized clinically by abdominal pain and elevated
levels of pancreatic enzymes (serum amylase, isoamylase,
and/or lipase). Abnormal exocrine and endocrine function
can also occur during an acute attack.
Banks and Freeman argue that acute pancreatitis is
characterized by two of either abdominal pain characteristic
of acute pancreatitis, serum amylase, and/or lipase raised
≥3 times over the upper limit of normal, and characteristic
ﬁndingsofacutepancreatitisoncomputedtomography(CT)
scan [96]. Based on this characterization, Manfredi and
Calza found 46 (3.7%) patients who presented with serum
amylase and/or lipase raised ≥3 times over the upper limit
of normal and acute pancreatitis on CT scan [60]. A further
120 (11.1%) patients presented only with serum amylase
and/or lipase raised ≥3 times over the upper limit of normal
and were thus classiﬁed as asymptomatic. Only 31 (2.9%)
patients had mild-to-moderate symptoms of abdominal
pain, with only 9 cases of clinically assessed pancreatits, none
of which required surgery or developed complications [60].
A relatively high incidence of at least one conﬁrmed
laboratory pancreatic abnormality, relating to at least two
serum pancreatic enzymes over a mean follow-up period of
33.6 consecutive months, was observed in this large study
[60]. The use of NRTIs like didanosine, stavudine, and
lamivudine and coadministration of other medications such
as pentamidine, cotrimoxazole, antituberculosis therapy,
cytotoxic chemotherapy, or their combination for at least
6 months were signiﬁcant risk factors for at least 3-fold
increases in serum pancreatic enzymes (P<0.05), as was
drug or alcohol abuse for at least 6 months (P = 0.04).
Opportunistic infections with potential pancreatic involve-
ment (cytomegalovirus, cryptosporidiosis, mycobacteriosis,
or disseminated tuberculosis) (P = 0.03), chronic liver,
and/or biliary disease (P = 0.01), current administration
of HAART regimen containing PIs (P = 0.05), hyper-
triglyceridemia for at least 6 months (P = 0.02), or a
combination of the above risk factors (P = 0.003) were also
associated with pancreatic toxicity [60]. The combination
of hyperamylasemia with either elevated isoamylasemia or
lipasemia was selected for evaluating laboratory abnormal-
ities, and the authors do not separate hyperamylasemia
from hyperlipasemia. Serum isoamylase and serum lipase
measurements are more speciﬁc when compared with serum
amylase alone for the diagnosis of pancreatitis [60]. Even
so, Van Dyke et al. chose to diagnose pancreatitis based on
total serum amylase rather than the more speciﬁc pancreatic
serum amylase, as the former is routinely monitored [27].
The PI lopinavir/ritonavir was associated with amylase
elevations in another study [32].
Pancreatitis likely attributable to didanosine was ob-
served in a couple of studies (Table 1)[ 27, 35]. Grade
≥3 serum amylase elevations were similar in patients receiv-
ing either didanosine/lamivudine/efavirenz or lamivudine/
zidovudine/efavirenz [97]. Hyperamylasemia and hyperuri-
cemia were eventual ﬁndings without clinical relevance in
another study [66]. Among NNRTIs, nevirapine was associ-
ated with pancreas-related toxicities [25, 47, 48], whereas
efavirenz was not [25].
Recurrent episodes of acute pancreatitis may also suggest
a misuse of alcohol or use of concomitant medication. There
isnomentionofhowmanydrinkerswereinalargestudy,yet
the incidence of symptomatic and asymptomatic cases was
similar between alcohol drinkers and abstainers [60].
6. HAART Interaction with
Alcohol Consumption
Hepatic injury is often more common in individuals with
alcohol abuse and in those with HCV coinfection. HAART-
induced hepatic injury has the potential to limit the use-
fulness of this medication in HIV treatment [63]. Twelve
(5.4%) patients were found to abuse alcohol in a sample of
222 patients, of which 84 (37.8%) were coinfected with HCV.
Alcohol abuse was identiﬁed as a risk factor for developing
hepaticinjuryofanygrade(OR3.42,95%CI1.04–11.19,P<
0.05),especiallyseverehepaticinjury(OR8.66,95%CI2.47–
30.40, P<0.05), measured by elevations in transaminase
levels[63].Alcoholintakegreaterthan40gperday(OR3.09,
95% CI 1.27–7.54, P = 0.01) was associated with a greater
risk of severe hepatotoxicity in a sample of 108 patients [65].
Fourteen (10.6%) patients were alcohol abusers in a
small sample of 132 HIV patients coinfected with HCV. Due
to the low number of alcohol abusers in this sample, no
association between alcohol abuse and hepatotoxicity was
observed [98]. Alcohol consumption, both at baseline and
duringfollow-up,wasnotlinkedtoprogressionofﬁbrosisby
≥1 stages among 135 patients coinfected with HCV, of which
31 (23.0%) patients had an alcohol intake of >50g/day [99].
Excessive alcohol consumption had no eﬀect on the
developmentofmild-to-moderaterash.However,severerash
plus/or hepatotoxicity was observed among 741 patients, of
which 163 (22.0%) abused alcohol (≥168g of alcohol per
week for women and ≥252g of alcohol per week for men)
[16].
Since the primary metabolic pathways of abacavir are
mediated by microsomal UDP glucuronyl transferase and
cytosolic alcohol dehydrogenase, use and misuse of alcohol
can lead to hepatotoxicity. A signiﬁcant pharmacokinetic
interactionwasfoundfollowingthecoadministrationofaba-
cavir and ethanol. Twenty-four HIV-positive men received
either a single 600mg dose of abacavir, 0.7g/kg ethanol
(the equivalent of 5 alcoholic drinks), or a 600mg dose of
abacavir plus 0.7g/kg ethanol on separate occasions. With
coadministration, there was a 41% increase in abacavir area
under the curve and a 26% increase in abacavir t1/2,w i t hn o
change in the pharmacokinetic proﬁle of ethanol [100].18 International Journal of Hepatology
While not all studies found an association between
alcohol consumption and a greater risk of HAART toxicity,
studies where such parameters are investigated often use
small population sizes, with a low proportion of alcohol
abusers, making it diﬃcult to uncover interactions.
7. Discussion
The present paper discusses hepatic, GI, and pancreatic
ADRs related to various ART drugs and drug combinations.
We also introduce a section on HSR, since HSRs encompass
many of the clinical entities of hepatic and GI representa-
tions. We further describe some of the interactions between
ART and other drugs and alcohol. Moreover, we brieﬂy
explore the inﬂuence of certain comorbidities, such as viral
hepatitis, on ART-induced hepatotoxicity.
As with all ART medications, many clinically signiﬁcant
interactions are possible with PIs. For example, atazanavir
cross-reacts with nevirapine. Atazanavir exposure is signiﬁ-
cantly lower when combined with this drug, and the risk of
nevirapine toxicity may increase due to increased nevirapine
exposure. In addition, atazanavir in combination with
efavirenz is not recommended in treatment-experienced
patients, since efavirenz signiﬁcantly lowers atazanavir expo-
sure. Concomitant didanosine/lamivudine exposure is not
recommended in ART-naive patients receiving unboosted
atazanavir due to potential toxicities. In addition, the viro-
logical response to abacavir may be diminished signiﬁcantly
bymultipleNRTI-associatedmutationsand/orbyreductions
in phenotypic susceptibility to abacavir. However, many
subjects showing evidence of baseline resistance to NRTIs
respond to abacavir.
Of particular relevance to the HIV-infected population
is coinfection with HCV. Hepatitis with aminotransferase
elevations was reported, and it should be appropriately
monitored [101].
Hepatocytotoxicity, or drug-induced liver injury, can be
classiﬁed based upon clinical presentation and laboratory
features, the mechanism of toxicity, and/or histological
ﬁndings. The presence of serum bilirubin raised >3t i m e s
over the upper limit of normal along with aminotransferase
elevations is associated with a more drastic prognosis than
isolated aminotransferase abnormalities [102], an observa-
tion known as Hy’s Law [103].
In addition to these acute hepatic presentations, some
drugs are associated with chronic histological inﬂammatory
changes and a clinical syndrome resembling autoimmune
hepatitis,whileotherscauseendothelialdamageorthrombo-
sis, leading to vascular complications such as venoocclusive
disease[104].Withdrawaloftheoﬀendingdrugusuallyleads
to reversal of the injury. The patterns of acute injury may
present as hepatocellular (cytotoxic) damage, cholestasis, a
mixed pattern of cytotoxic and cholestatic injury, or, less
commonly, steatosis [102]. Discontinuation of the oﬀending
agent usually results in complete recovery, although the
prognosis is generally worse in patients with hepatocellular
injury presenting with jaundice when compared to cytotoxic
injury alone.
HIV per se may inﬂuence the ultrastructural architecture
of the liver. In the liver of a patient living with AIDS, Phillips
et al. found tubular structures mainly in the cytoplasm
of endothelial cells and less frequently in Kupﬀer cells,
macrophages, ﬁbroblasts, and biliary cells. These changes
were associated with the endoplasmic reticulum, represent-
ing a cellular response to virus-induced injury [105].
Drug-induced steatohepatitis may also resemble alco-
holic liver disease [106, 107]. In addition, ethnicity plays a
role in antiretroviral-induced toxicity [108].
Some of the subjects living with HIV that were included
in these studies have a history or past or present alcohol
consumption. From a histological point of view, alcoholic
hepatitis presents enlargement of hepatocytes that may
increase the vascular pressure in the acinus [109]. Mitochon-
drial changes, including megamitochodria or irregular mito-
chondria, as well as Mallory bodies, are also encountered.
Mallory bodies (alcoholic hyalin) correspond to cytokeratine
conglomerations of proteins that form ﬁlaments.
Thepredominantcellintheliveristhehepatocyte,which
contains abundant cytoplasm. There are little amounts of
carbohydrates and phospholipids in ﬁlaments seen in hepa-
tocytes. These cytokeratine ﬁlaments represent an abnormal
expression of the cytoskeleton. Ultrastructurally, irregular
inclusions, which range from small conglomerates of ﬁla-
ments to large inclusions, occupy most of the cytoplasm
[105]. A wide range of other ultrastructural changes in alco-
holic liver disease can be seen in conjunction with HAART,
such as cell necrosis, increased peroxisome numbers, and
crystalloid inclusions. Also, there are infrequent bile duct
proliferation and ground glass cytoplasmic inclusions that
can be resolved after alcohol abstinence.
The genetic value of UGT in PI-induced hyperbiliru-
binemia is further discussed [110]. Rotger et al. showed
that individuals homozygous for the A(TA)7TAA allele of
UGT1A1∗28 enzyme receiving atazanavir or indinavir were
at increased risk of experiencing hyperbilirubinemia in the
jaundice ranges. They studied in parallel a group of patients
that have not been genotyped for UGT1A1 allele before
prescribing atazanavir or indinavir as ﬁrst-line agents versus
patients that have been genotyped for UGT1A1∗28. The
“genotype-guided ART” narrowed the use of atazanavir or
indinavir to individuals without the UGT1A1∗28 allele. The
authors conclude that genetic screening would lead to a
theoretical 75% reduction in the incidence of hyperbiliru-
binemia in the jaundice range. The high incidence of the
UGT1A1∗28 allele might lead to high risk of developing
jaundice in the setting of Gilbert syndrome when exposed
to speciﬁc PIs [110]. UGT1A1 promoter A(TA)7TAA variant
was most common among African Americans and least
common among subjects of Asian origin [111]. Therefore
the use of genetic screening for the A(TA)7TAA allele before
initiation of antiretroviral therapy is controversial [112].
Ideally, genetic testing for this allele, in conjunction with
testing for markers of immunotoxicity such as lymphocyte
toxicity assay, may be used in the future in the clinical setting
to prevent, diagnose, or monitor drug-induced ADRs in
people living with HIV [113].International Journal of Hepatology 19
We conclude that antiviral pharmacodynamics is aﬀected
by a broad array of factors ranging from individual pharma-
cokinetic and pharmacogenetic parameters, to medication
adherence and drug-drug interactions. Therefore, therapeu-
tic and drug monitoring of HAART plays an important
role. Using laboratory techniques to identify phenotypic
susceptibilities, as well as knowing the interactions between
ART and other drugs or herbal medicines, might enable
a safer use of this beneﬁcial type of medication in HIV
patients. Adding to the complexity, many HIV-infected
patients are unable to keep therapeutic medication safe
due to their behavior patterns, such as alcohol misuse.
Lack of pharmacovigilance is associated with HIV disease
progression as well as toxicities.
Themajorobjectiveofthisarticleistoincreaseawareness
on the possible toxicity of therapeutics prescribed in HIV.
Moreover, there are other health products including tradi-
tional small molecule drugs, natural health products, biolog-
ics, and biotechnology products that are prescribed in HIV.
These products may cause not only signiﬁcant liver direct
toxicity but also unpredictable, idiosyncratic hepatotoxicity.
Therefore, in the process of achieving pharmacovigilance
objectives, the investigational approach used for a particular
therapeuticmayhavetobeindividualizedbasedonthesafety
characteristics of the product as well as its proposed clinical
application.
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